Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106837 | 0.82 | CYP1A2 (0.37) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL17080185 | 0.76 | NLRP3 (0.34) | ACACB | |
| SCHEMBL4200153 | 0.72 | ALDH1A1 (0.45) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL25193722 | 0.72 | MMP2 (0.36) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL2072199 | 0.71 | HSD17B10 (0.41) | CPB2FPR2CYP11B1 | |
| SCHEMBL2072202 | 0.71 | HSD17B10 (0.41) | CPB2FPR2CYP11B1 | |
| SCHEMBL29702174 | 0.71 | SIRT2 (0.35) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL13550944 | 0.71 | SIRT2 (0.44) | MMP2MMP9MMP8MMP13SIRT2 | |
| SCHEMBL103684 | 0.70 | CYP26A1 (0.34) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL5737786 | 0.70 | SIRT2 (0.43) | MMP2MMP9MMP8MMP13SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| EP-2183255-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | MMP2 4587/4885MMP9 3815/4885MMP8 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.